Divi's Labs reported Q1 FY27 consolidated revenue of ₹3,144 Cr (up from ₹2,529 Cr YoY) and PAT of ₹902 Cr (up from ₹545 Cr YoY), with 10% constant currency standalone revenue growth.

Custom Synthesis drove 60% of revenue.

Management is confident in achieving double-digit growth, propelled by three major capex programs nearing completion and a strong peptide pipeline, including capacity expansion with 3,000-liter SPPS.

The company is actively managing elevated solvent costs and global supply chain challenges through strategic inventory stocking and backward integration efforts, with Unit 3 playing a crucial role.

Divi's emphasizes its unique integrated peptide manufacturing capabilities for future growth.